HRSA discloses manufacturers approved for revised 340B rebate pilot
Published . Updated .
Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump administration’s first attempt at kickstarting a rebate pilot.
Directly affected
- No company is named in this report.
Indirectly affected
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump administration’s first attempt at kickstarting a rebate pi…
Source: Healthcare Dive
Price since this story was published: Davita (DVA)
Since the first closing price after “HRSA discloses manufacturers approved for revised 340B rebate pilot,” Davita (DVA) is +4.71%. The S&P 500 fund (SPY) is -0.40% over the same days, a +5.10% difference versus the market.
Filings that name Davita (DVA) around 1 Oct 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 2 days before publication, inside 30 days. The filing is listed beside the story “HRSA discloses manufacturers approved for revised 340B rebate pilot.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 20 days before publication, inside 30 days. The filing is listed beside the story “HRSA discloses manufacturers approved for revised 340B rebate pilot.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “HRSA discloses manufacturers approved for revised 340B rebate pilot.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Davita (DVA)
Companies carried with this story
- DVA Davita
In “HRSA discloses manufacturers approved for revised 340B rebate pilot,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
In “HRSA discloses manufacturers approved for revised 340B rebate pilot,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 1 Oct 2026 story “HRSA discloses manufacturers approved for revised 340B rebate pilot.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “HRSA discloses manufacturers approved for revised 340B rebate pilot,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “HRSA discloses manufacturers approved for revised 340B rebate pilot,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “HRSA discloses manufacturers approved for revised 340B rebate pilot,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Davita (DVA)
“HRSA discloses manufacturers approved for revised 340B rebate pilot” (1 Oct 2026) reaches Davita (DVA) through this story.
What ties Davita (DVA) to the headline is this: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC) is here too. Its reason reads: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Davita (DVA)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. DVA traded between 174.10 and 189.79 across 20 sessions. The latest close on file is 187.06.
What the saved facts support for Davita (DVA)
46 out of 100
“HRSA discloses manufacturers approved for revised 340B rebate pilot” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.